|
UPLC System and SEC Columns Booth 3155. Waters UPLC analytical SEC solution for characterizing proteins and their aggregates combines new ACQUITY UPLC BEH200, 1.7-µm SEC columns with the ACQUITY UPLC system for identifying and quantifying glycan profiles from biopharmaceutical proteins.
This solution allows labs to comply with U.S. FDA regulations that require firms developing and manufacturing therapeutic proteins to separate and quantify monoclonal antibodies (mAb) and their aggregates accurately, ensuring the efficacy and safety of a biopharmaceutical product.
The SEC columns are suited for scientists seeking to apply the power of UPLC technology for accurate, precise, high-throughput quantitative analysis of proteins, such as therapeutic mAbs. Each column features ACQUITY UPLC eCord technology for recording critical individual column use parameters.
BEH200 SEC columns are produced with the Waters Designed for Six Sigma Phase II ACQUITY UPLC column manufacturing process, ensuring long-term performance by maximizing efficiency and minimizing column-to-column variability.
Waters Corporation
34 Maple Street
Milford MA 01757
Phone: 508-482-2614
Fax: 508-482-2674
http://www.waters.com
Company’s Other Products
|
|
|
|
|
|
